Evidence Analysis

It is a challenge for health plans and clinicians to distill and analyze volumes of clinical evidence to determine likely clinical, financial, and risk impacts. This is what we do.

Accessed through the Hayes Knowledge Center, the Evidence Analysis Solution addresses the following fundamental questions to help our clients determine coverage positions:

  • Does the technology improve health outcomes?
  • Are there other benefits associated with the technology?
  • What harms might be associated with the technology?
  • Have patient selection criteria been established for the technology?
  • For which patients might the technology provide a benefit?

ChemoFx Assay (Helomics)

This report evaluates the analytical validity, clinical validity, and clinical utility of the ChemoFx test, an in vitro patient tumor–derived cell culture assay that determines how cancer cells may respond to chemotherapeutic agents in order to help guide physicians’ treatment decisions in patients with gynecologic cancer.

read more